Innovating Works
IMI2-2020-23-04
IMI2-2020-23-04: Optimal treatment for patients with solid tumours in Europe through Artificial Intelligence
Specific Challenge:Demands of cancer care in Europe continue to increase significantly, with the number of incident cancer cases in Europe projected to increase by 14.1% by 2030. This leads to a growing demand for innovative cancer treatments among patients, payers, physicians, and society. At the same time, the understanding of the complex biology of cancer is growing, and as a result, pharmaceutical companies are developing a multitude of new therapeutic agents.
Sólo fondo perdido 0 €
Europeo
Esta convocatoria está cerrada Esta línea ya está cerrada por lo que no puedes aplicar. Cerró el pasado día 29-09-2020.
Se espera una próxima convocatoria para esta ayuda, aún no está clara la fecha exacta de inicio de convocatoria.
Por suerte, hemos conseguido la lista de proyectos financiados!
Presentación: Consorcio Consorcio: Esta ayuda está diseñada para aplicar a ella en formato consorcio.
Número mínimo de participantes.
Esta ayuda financia Proyectos: Objetivo del proyecto:

Specific Challenge:Demands of cancer care in Europe continue to increase significantly, with the number of incident cancer cases in Europe projected to increase by 14.1% by 2030. This leads to a growing demand for innovative cancer treatments among patients, payers, physicians, and society. At the same time, the understanding of the complex biology of cancer is growing, and as a result, pharmaceutical companies are developing a multitude of new therapeutic agents.

This trend for new, effective therapies creates more treatment options for patients. However, it confronts physicians with an increasingly expanding number of potential therapeutic options, which each need to be understood and adopted effectively. To become familiar with the huge volume of available information, physicians need to learn continuously about medical guideline changes and marketed treatments. In conclusion, future decision-making processes will become ever-more complex, with the potential outcome of sub-optimal or even incorrect treatment choices being made. Furthermore, some patients have disease characteristics for which evidence of guideline recommendations is scarce and physicians lack infor... ver más

Specific Challenge:Demands of cancer care in Europe continue to increase significantly, with the number of incident cancer cases in Europe projected to increase by 14.1% by 2030. This leads to a growing demand for innovative cancer treatments among patients, payers, physicians, and society. At the same time, the understanding of the complex biology of cancer is growing, and as a result, pharmaceutical companies are developing a multitude of new therapeutic agents.

This trend for new, effective therapies creates more treatment options for patients. However, it confronts physicians with an increasingly expanding number of potential therapeutic options, which each need to be understood and adopted effectively. To become familiar with the huge volume of available information, physicians need to learn continuously about medical guideline changes and marketed treatments. In conclusion, future decision-making processes will become ever-more complex, with the potential outcome of sub-optimal or even incorrect treatment choices being made. Furthermore, some patients have disease characteristics for which evidence of guideline recommendations is scarce and physicians lack information about real-world treatment outcomes. Hence, the challenges to be addressed are assisted guideline-based decision-making and the discovery of knowledge about treatment outcomes in real-world settings. As the latter challenge requires analysis of large data sets, the application of Artificial Intelligence (AI) will be a key technology.

Please refer to Call topic text.


Scope:The scope of this call topic is to establish guideline-based decision support and platform solutions to generate knowledge discovery for breast, lung and prostate cancer with applicability to other indications, in several European (EU member states and H2020 associated countries) ‘model’ regions. The funded action will focus only on breast, lung and prostate cancer. These indications show a high number of cases per year, a high, unmet medical need, multiple available therapeutic options and a fast-evolving treatment environment. Expansion to other indications is not part of the funded action but a proposed solution should allow for expansion afterwards. The three core objectives of this call topic are as follows:

Objective 1: Establish a guideline-based decision support for prioritised indications

Objective 2: Establish a structured and interoperable data platform to unlock real-world-data potential in an oncology network

Objective 3: Leverage the real-world-data gathered by the action to establish an AI-knowledge base and support treatment decisions for prioritized indications.

Please refer to Call topic text.


Expected Impact:In their proposals, applicants should describe how the outputs of the project will contribute to the following impacts and include wherever possible baseline, targets and metrics to measure impact.

An explainable AI-based knowledge discovery platform should enable the development of data-driven solutions with the goal to sustainably improve oncologic treatments throughout the EU and beyond; The results obtained from these model regions are expected to be of relevance to countries with different socioeconomic backgrounds;The platform should allow oncologists to save valuable time due to the automatic data gathering and facilitated guideline-based assessment; In addition, physician-patient communication and shared decision making should be supported which might improve proactive therapy involvement to accomplish increases in individual quality of life as well as overall patient satisfaction;The platform may also allow research questions from various stakeholders to be answered through data analysis and data pooling as well as data extraction. Besides overall survival, this could include real-world quality of life (QoL) and safety evaluations of new therapies as well as novel combinations under real world conditions. This can potentially contribute to value-based healthcare assessments at EU level;The solutions provided by a public-private consortium will significantly benefit European society: patients receive optimal personalised treatment; physicians are supported in complex decision-making processes; and payers as well as pharmaceutical companies receive information about real world treatment outcomes as a foundation for value-based healthcare approaches; The topic is well aligned with the EU Commission’s strategy to develop a European Health Data Space and Europe’s Beating Cancer Plan. Please refer to Call topic text.


ver menos

Temáticas Obligatorias del proyecto: Temática principal:

Características del consorcio

Ámbito Europeo : La ayuda es de ámbito europeo, puede aplicar a esta linea cualquier empresa que forme parte de la Comunidad Europea.
Tipo y tamaño de organizaciones: El diseño de consorcio necesario para la tramitación de esta ayuda necesita de:

Características del Proyecto

Requisitos de diseño: Duración:
Requisitos técnicos: Specific Challenge:Demands of cancer care in Europe continue to increase significantly, with the number of incident cancer cases in Europe projected to increase by 14.1% by 2030. This leads to a growing demand for innovative cancer treatments among patients, payers, physicians, and society. At the same time, the understanding of the complex biology of cancer is growing, and as a result, pharmaceutical companies are developing a multitude of new therapeutic agents. Specific Challenge:Demands of cancer care in Europe continue to increase significantly, with the number of incident cancer cases in Europe projected to increase by 14.1% by 2030. This leads to a growing demand for innovative cancer treatments among patients, payers, physicians, and society. At the same time, the understanding of the complex biology of cancer is growing, and as a result, pharmaceutical companies are developing a multitude of new therapeutic agents.
¿Quieres ejemplos? Puedes consultar aquí los últimos proyectos conocidos financiados por esta línea, sus tecnologías, sus presupuestos y sus compañías.
Capítulos financiables: Los capítulos de gastos financiables para esta línea son:
Personnel costs.
Los costes de personal subvencionables cubren las horas de trabajo efectivo de las personas directamente dedicadas a la ejecución de la acción. Los propietarios de pequeñas y medianas empresas que no perciban salario y otras personas físicas que no perciban salario podrán imputar los costes de personal sobre la base de una escala de costes unitarios
Purchase costs.
Los otros costes directos se dividen en los siguientes apartados: Viajes, amortizaciones, equipamiento y otros bienes y servicios. Se financia la amortización de equipos, permitiendo incluir la amortización de equipos adquiridos antes del proyecto si se registra durante su ejecución. En el apartado de otros bienes y servicios se incluyen los diferentes bienes y servicios comprados por los beneficiarios a proveedores externos para poder llevar a cabo sus tareas
Subcontracting costs.
La subcontratación en ayudas europeas no debe tratarse del core de actividades de I+D del proyecto. El contratista debe ser seleccionado por el beneficiario de acuerdo con el principio de mejor relación calidad-precio bajo las condiciones de transparencia e igualdad (en ningún caso consistirá en solicitar menos de 3 ofertas). En el caso de entidades públicas, para la subcontratación se deberán de seguir las leyes que rijan en el país al que pertenezca el contratante
Amortizaciones.
Activos.
Otros Gastos.
Madurez tecnológica: La tramitación de esta ayuda requiere de un nivel tecnológico mínimo en el proyecto de TRL 5:. Los elementos básicos de la innovación son integrados de manera que la configuración final es similar a su aplicación final, es decir que está listo para ser usado en la simulación de un entorno real. Se mejoran los modelos tanto técnicos como económicos del diseño inicial, se ha identificado adicionalmente aspectos de seguridad, limitaciones ambiéntales y/o regulatorios entre otros. + info.
TRL esperado:

Características de la financiación

Intensidad de la ayuda: Sólo fondo perdido + info
Fondo perdido:
0% 25% 50% 75% 100%
Please read carefully all provisions below before the preparation of your application.
The IMI2 JU 23rd Call for proposals topics text as well as the Call Conditions are available here.
The budget breakdown for this Call, along with the information below, are given at the end of the Call topics text, in the Call Conditions section.
1.   Eligible countries: described in article 10(2) of the Rules for participation in Horizon 2020 and in article 1 of the Commission Delegated Regulation related to IMI JU.
2.   Eligibility and admissibility conditions: described in the IMI2 Manual for evaluation, submission and grant award. See also the Commission Delegated Regulation related to IMI JU.
Proposal page limits and layout: Please refer to Part B of the proposal template in the submission tool below.
3.   Evaluation:
Submission and evaluation process, including evaluation criteria and procedure, scoring and threshold are described in the IMI2 Manual for submission, evaluation and grant award. See also the proposal templates for your specific action in section 5, below.
4. Indicative time for evaluation and grant agreement:
Notification of outcomes of stage 1 evaluations: maximum 5 months from deadline for submitting proposals.
Notification of outcomes of stage 2 evaluations: maximum 5 months from deadline for submitting full proposals.
Signature of grant agreements: maximum...
Please read carefully all provisions below before the preparation of your application.
The IMI2 JU 23rd Call for proposals topics text as well as the Call Conditions are available here.
The budget breakdown for this Call, along with the information below, are given at the end of the Call topics text, in the Call Conditions section.
1.   Eligible countries: described in article 10(2) of the Rules for participation in Horizon 2020 and in article 1 of the Commission Delegated Regulation related to IMI JU.
2.   Eligibility and admissibility conditions: described in the IMI2 Manual for evaluation, submission and grant award. See also the Commission Delegated Regulation related to IMI JU.
Proposal page limits and layout: Please refer to Part B of the proposal template in the submission tool below.
3.   Evaluation:
Submission and evaluation process, including evaluation criteria and procedure, scoring and threshold are described in the IMI2 Manual for submission, evaluation and grant award. See also the proposal templates for your specific action in section 5, below.
4. Indicative time for evaluation and grant agreement:
Notification of outcomes of stage 1 evaluations: maximum 5 months from deadline for submitting proposals.
Notification of outcomes of stage 2 evaluations: maximum 5 months from deadline for submitting full proposals.
Signature of grant agreements: maximum 3 months from the date of informing successful applicants.
5.   Proposal templates, evaluation forms and model grant agreements (MGA):
IMI2 Research and Innovation Action (IMI2-RIA) and Innovation Action (IMI2-IA):
Standard evaluation form
Proposal templates are available after entering the submission tool
Proposal template stage 1
Proposal template stage 2
IMI2 Model Grant Agreement
Clinical trial template - The clinical trial template is required only at stage 2! Therefore, in the Proposal Submission Form at stage 1, the answer options to the question "Are clinical studies/trials/investigations included in the work plan of this project?” are disabled.
 
6.   Open access must be granted to all scientific publications resulting from Horizon 2020 actions.
Where relevant, proposals should also provide information on how the participants will manage the research data generated and/or collected during the project, such as details on what types of data the project will generate, whether and how this data will be exploited or made accessible for verification and re-use, and how it will be curated and preserved.
Open access to research data
The Open Research Data Pilot has been extended to cover all Horizon 2020 topics for which the submission is opened on 26 July 2016 or later. Projects funded under this topic will therefore by default provide open access to the research data they generate, except if they decide to opt-out under the conditions described in Annex L of the H2020 main Work Programme. Projects can opt-out at any stage, that is both before and after the grant signature.
Note that the evaluation phase proposals will not be evaluated more favourably because they plan to open or share their data, and will not be penalised for opting out.
Open research data sharing applies to the data needed to validate the results presented in scientific publications. Additionally, projects can choose to make other data available open access and need to describe their approach in a Data Management Plan.
Projects need to create a Data Management Plan (DMP), except if they opt-out of making their research data open access. A first version of the DMP must be provided as an early deliverable within six months of the project and should be updated during the project as appropriate. The Commission already provides guidance documents, including a template for DMPs. See the Online Manual.
Eligibility of costs: costs related to data management and data sharing are eligible for reimbursement during the project duration.
The legal requirements for projects participating in this pilot are in the article 29.3 of the Model Grant Agreement.
Members of consortium are required to conclude a consortium agreement prior to the signature of the grant agreement.
7. Additional documents:
Summary of the most relevant provisions for participating in IMI2 actions
IMI2 Annual Work Plan 2020
IMI JU derogation to H2020 Rules for Participation
Horizon 2020 Rules for Participation
Horizon 2020 Regulation of Establishment
Horizon 2020 Specific Programme
Garantías:
No exige Garantías
No existen condiciones financieras para el beneficiario.

Información adicional de la convocatoria

Efecto incentivador: Esta ayuda tiene efecto incentivador, por lo que el proyecto no puede haberse iniciado antes de la presentación de la solicitud de ayuda. + info.
Respuesta Organismo: Se calcula que aproximadamente, la respuesta del organismo una vez tramitada la ayuda es de:
Meses de respuesta:
Muy Competitiva:
No Competitiva Competitiva Muy Competitiva
No conocemos el presupuesto total de la línea
Minimis: Esta línea de financiación NO considera una “ayuda de minimis”. Puedes consultar la normativa aquí.

Otras ventajas

Sello PYME: Tramitar esta ayuda con éxito permite conseguir el sello de calidad de “sello pyme innovadora”. Que permite ciertas ventajas fiscales.
H2020-JTI-IMI2-2020-23-two-stage Optimal treatment for patients with solid tumours in Europe through Artificial Intelligence Specific Challenge:Demands of cancer care in Europe continue to increase significantly, with the number of incident cancer cases in Europe p...
Sin info.
IMI2-2020-23-01 Returning Clinical Trial Data to study participants within a GDPR compliant and approved ethical framework
en consorcio: Specific Challenge:A large amount of high-quality health data is collected during clinical studies (interventional and non-interventional),...
Cerrada hace 4 años | Próxima convocatoria prevista para el mes de
IMI2-2020-23-04 Optimal treatment for patients with solid tumours in Europe through Artificial Intelligence
en consorcio: Specific Challenge:Demands of cancer care in Europe continue to increase significantly, with the number of incident cancer cases in Europe p...
Cerrada hace 4 años | Próxima convocatoria prevista para el mes de
IMI2-2020-23-05 Shortening the path to Rare Disease diagnosis by using newborn genetic screening and digital technologies
en consorcio: Specific Challenge:Approximately 5,000-8,000 distinct rare diseases (RD) affect 6-8% of the EU population i.e. between 27 and 36 million peo...
Cerrada hace 4 años | Próxima convocatoria prevista para el mes de
IMI2-2020-23-02 Modelling the impact of monoclonal antibodies and vaccines on the reduction of antimicrobial resistance
en consorcio: Specific Challenge:Vaccines and monoclonal Antibodies (mAb) may reduce antimicrobial resistance (AMR). However, individual vaccine developer...
Cerrada hace 4 años | Próxima convocatoria prevista para el mes de
IMI2-2020-22-01 Restricted Call to maximise impact of IMI2 JU objectives and scientific priorities
en consorcio: Specific Challenge:A major challenge in life sciences, in particular within the medicines development process, is the scale of the investmen...
Cerrada hace 4 años | Próxima convocatoria prevista para el mes de